Compare · GLP-1 agonist
Semaglutide vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Semaglutide | Survodutide | |
|---|---|---|
| Evidence | 10/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.
Survodutide
Survodutide (its lab code is BI 456906) is an experimental injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has more real human research behind it than most peptides sold online, including several carefully run trials that compared it against a placebo (a…